Danish Trial Tests Whether Transoral Ultrasound Can Sharpen Peritonsillar Abscess Diagnosis
Peritonsillar abscess PTA sits at a difficult intersection of urgency and uncertainty. The condition can demand drainage and antibiotics, yet the closely related peritonsillar cellulitis is treated with antibiotics alone. When the two look alike on bedside examination, clinicians risk either missing a drainable collection or performing an unnecessary invasive procedure. This protocol from Denmark is designed to test whether adding transoral ultrasound to the physical examination can improve that decision-making process in a real outpatient ENT setting.
The clinical problem is straightforward, even if the diagnosis is not. PTA is a common deep neck infection, and the classic bedside picture—fever, unilateral sore throat, trismus, dysphagia, peritonsillar swelling, and uvular deviation—can also appear in cellulitis without pus formation. Physical examination alone often cannot separate the two with confidence. That uncertainty matters because the treatment paths diverge immediately: drainage for PTA, antibiotics alone for PTC. In a condition where swelling, pain, and airway concerns can escalate quickly, diagnostic clarity is not academic.
Computed tomography has long been available as a confirmatory tool, but it carries radiation exposure and can slow treatment. Needle aspiration is also widely used, yet repeated attempts without pus retrieval expose patients to avoidable discomfort and procedural risk. The appeal of ultrasound is easy to understand: it is radiation-free, non-invasive, and can be performed at the point of care by the treating ENT physician. In the peritonsillar space, a high-frequency hockey-stick transducer can bring the infected region into view through the oral cavity, offering a direct image of the suspected collection rather than an indirect inference from symptoms alone.
One sentence captures the rationale for the trial: ultrasound may prevent a misstep at the bedside.
A Cluster-Randomized Design Built Around Routine ENT Workflow
Investigators are running a prospective, multicenter cluster randomized trial across four Danish hospitals: Rigshospitalet, North Zealand Hospital Hillerød, Zealand University Hospital Køge, and Aarhus University Hospital. The protocol is registered at ClinicalTrials.gov as NCT07577232. Enrollment is structured by weekly clusters rather than individual randomization, so all eligible patients presenting in a given week are assigned to the same study arm. That design reduces contamination between diagnostic strategies inside the same clinic workflow and better reflects how clinicians actually work.
Participants are adults referred to the ENT outpatient clinic with suspected PTA, usually from primary care or the emergency department. They are assigned to either clinical examination alone or clinical examination plus surgeon-performed transoral ultrasound before the initial diagnostic decision is made. No written informed consent is required, but patients receive study information and may decline participation or withdraw later. The trial includes patients from 22 May 2025 through 15 November 2026, or until 368 participants have been enrolled, whichever comes first.
This is a pragmatic diagnostic study, not a drug trial. The intervention is not an experimental treatment but an imaging extension of the exam. Even so, the protocol is clinically consequential because diagnostic errors in PTA can trigger the wrong intervention immediately. A false-positive result can lead to aspiration or tonsillectomy that was never needed. A false-negative result can delay drainage in a patient who actually has pus under pressure.
Why the Ultrasound Question Remains Open
The rationale for the study is anchored in earlier randomized work, but those data do not settle the issue. One small emergency department trial included 28 patients and found 100% diagnostic accuracy in the ultrasound arm versus 64% in controls, though the sample was small and the operator was supervised throughout. A later ENT outpatient study with 95 patients found fewer needle aspiration attempts with ultrasound but no statistically significant improvement in diagnostic accuracy. Differences in operator experience likely explain part of that discrepancy, since multiple residents were still early in their learning curve in the larger trial.
A meta-analysis cited in the protocol reported 91% specificity and 75% sensitivity for transoral ultrasound in distinguishing PTA from cellulitis. Those numbers are encouraging, but they also leave room for both false reassurance and false alarm. In a disease where management hinges on whether pus is actually present, modestly imperfect sensitivity and specificity can have immediate bedside consequences. The present trial is meant to test whether performance improves when the technique is deployed by ENT clinicians in a larger, multicenter setting and whether experience changes its value in routine care.
The Endpoint is Diagnostic Accuracy, Not Merely Imaging Performance
Primary outcomes are sensitivity, specificity, and overall diagnostic accuracy. The protocol also anticipates the practical question clinicians care about most: whether the imaging result changes management in a way that improves, rather than complicates, care. Because all patients receive standard treatment if PTA is suspected, including needle aspiration or tonsillectomy and antibiotics, the trial stays aligned with accepted management while evaluating whether ultrasound improves the precision of those decisions.
The choice of endpoint reflects the biology of the disease. PTA is a purulent collection; PTC is inflammatory swelling without pus. Ultrasound can, in principle, visualize the fluid boundary that separates the two. If the image quality and operator skill are sufficient, the tool should improve diagnostic certainty exactly where anatomy becomes clinically decisive. If not, it may add time, cost, and workflow complexity without changing outcomes.
That operational burden is explicitly part of the concern. The protocol names increased equipment costs, prolonged consultation time, and greater workflow complexity as reasons not to adopt the technique prematurely. Those tradeoffs are realistic in ENT practice, where outpatient throughput and procedural efficiency matter. A diagnostic tool that improves confidence but slows the clinic may still be worth using, but only if the gains are large enough to justify the added friction.
What This Protocol Can and Cannot Answer Yet
This study will not tell clinicians whether transoral ultrasound cures PTA or replaces drainage. It will answer a narrower but important question: does adding ultrasound to the bedside exam improve the accuracy of distinguishing abscess from cellulitis in a multicenter ENT population? The protocol is powered for 368 patients, making it the largest randomized effort described here to assess the role of transoral ultrasound in suspected PTA.
The final readout will need to be judged carefully. Diagnostic tests in a real clinic are judged not only by sensitivity and specificity, but by whether they change the right decisions at the right time. In PTA, the stakes are immediate because the wrong branch point leads either to unnecessary invasive treatment or to delayed source control. This trial is built to measure that branch point with enough scale to move beyond small single-center experience, but until results arrive, ultrasound remains a promising adjunct rather than a settled standard.
- • ClinicalTrials.gov Protocol (NCT07577232): https://clinicaltrials.gov/study/NCT07577232
- • PLOS ONE DOI 10.1371/journal.pone.0362695: https://doi.org/10.1371/journal.pone.0362695